250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 50 Biotechnology Startup Investors

A list of 50 angel investors and VC funds that invest in Biotechnology startups. We rank investors based on the number of investments they made in Biotechnology companies. This investor list updates every month.

Top 50 Biotechnology Startup Investors

Investor Biotechnology investments
ARCH Venture Partners 125
OrbiMed 99
Sofinnova Partners 92
Alexandria Venture Investments 87
Novo Holdings 80
Versant Ventures 79
New Enterprise Associates 79
F-Prime Capital 77
Atlas Venture 70
Khosla Ventures 67
5AM Ventures 65
Polaris Partners 65
RA Capital Management 64
MPM Capital 64
Innova Memphis 63
Qiming Venture Partners 62
Novartis Venture Fund 58
Third Rock Ventures 58
M Ventures 57
UK Innovation & Science Seed Fund 54
Bpifrance 53
Canaan Partners 52
Sequoia Capital China 52
HTGF | High-Tech Gruenderfonds 50
BioAdvance 50
Takeda Ventures 47
Lux Capital 47
Pfizer Venture Investments 47
Boehringer Ingelheim Venture Fund 47
Google Ventures 46
Fifty Years 46
Lilly Asia Ventures 45
Andreessen Horowitz 45
Sofinnova Investments 45
EQT Life Sciences 45
SR One 44
DCVC 44
Parkwalk Advisors 43
Seventure Partners 42
KdT Ventures 41
Hatteras Venture Partners 41
Casdin Capital 41
The Column Group 40
Connecticut Innovations 40
Frazier Healthcare Partners 39
Forbion Capital Partners 39
HealthCap 38
Amgen Ventures 38
Northpond Ventures 38
Oxford Science Enterprises 38
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
ARCH Venture Partners VC Fund · Chicago, Illinois, United States · 19 investments in the past 12 months
ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, China, United Kingdom
Portfolio highlights
  • Vilya — Vilya is a biotechnology company developing a novel class of drugs that precisely target the biology of disease. The company aims to create new medicines to leverage computing to make high throughput screening obsolete and cure diseases.
  • Metsera — Metsera operates as a clinical-stage biopharmaceutical company.
  • Xaira Therapeutics — Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
OrbiMed VC Fund · New York, New York, United States · 46 investments in the past 12 months
Leading Global Healthcare Platform with Deep Proprietary Resources and Global Industry Coverage.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, China, Israel
Portfolio highlights
  • TriSalus Life Sciences — Surefire Medical, based in Westminster, Colorado, was founded in 2009 to develop a novel infusion system for the interventional radiology market. The Surefire's Infusion System is designed to precisely deliver embolic agents through the sophisticated expandable tip portion of its catheter. Because of this differentiated expandable tip, whichcollapses in forwarding flow to maintain blood flow and dynamically expands to the vessel wall in reverse flow to minimize reflux, Surefire's Infusion System is designed to substantially reduce damage to healthy tissue.
  • Corvus Pharmaceuticals — Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. With accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
  • Sparrow Pharmaceuticals — Sparrow Pharmaceuticals is an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess.
Sofinnova Partners VC Fund · Paris, Ile-de-France, France · 20 investments in the past 12 months
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • France, United States, United Kingdom
Portfolio highlights
  • Cure51 — Cure51 mission is to create a database of cancer survivors to leverage their exceptional biological features and find new drugs to cure Cancer.
  • Bioptimus — Our mission is to build the first universal AI foundation model for biology to fuel breakthrough discoveries and accelerate innovations in biomedicine and beyond.
  • MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
Alexandria Venture Investments VC Fund · Pasadena, California, United States · 13 investments in the past 12 months
Alexandria Venture Investments is a venture capital firm that develops work in real estate technology, and healthcare sectors. The company's strategic venture capital platform is Alexandria Venture Investments. Since its inception in 1996, the company has invested in disruptive life science, agrifood tech, and technology companies that aredeveloping transformative new modalities and platforms to meaningfully improve human health.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, France, Canada
Portfolio highlights
  • Umaro Foods — Umaro Foods specializes in developing a plant-based protein source from ocean-farmed seaweed.
  • Tome Biosciences — Tome Biosciences is a biotechnology company that develops programmable gene insertion technology. Using CRISPR, its technologies allow them to insert any genetic sequence of any size at any location into any genome.
  • Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
Novo Holdings VC Fund · Hellerup, Hovedstaden, Denmark · 17 investments in the past 12 months
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series A, Series B, Series C
  • United States, Denmark, United Kingdom
Portfolio highlights
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • CIRCTEC — CIRCTEC is an innovator and operator of pyrolysis technology to recycle waste into renewable fuels and circular chemicals. It focus is on innovation and technology leadership, scaling sustainability in the chemical, petrochemical and oil sectors.
  • CARGO Therapeutics — CARGO Therapeutics develops CAR T-cell therapy to overcome cancer treatment resistance and address access barriers so that more patients can benefit from potentially curative therapies. The company is on a mission to outwit cancer by developing best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite commercially available autologousCARs advancements, these treatments are curative for less than half of all cancer patients. Furthermore, far too many patients are unable to access these potentially curative therapies due to other obstacles such as manufacturing, supply constraints, long turnaround times, and reimbursement barriers. CARGO's team is intensely focused on pursuing novel solutions to improve cancer treatment outcomes and experiences.
Versant Ventures VC Fund · Menlo Park, California, United States · 7 investments in the past 12 months
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • United States, Switzerland, Canada
Portfolio highlights
  • Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
  • SixPeaks Bio — SixPeaks is developing a pipeline of medicines for healthy weight loss.
  • Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
New Enterprise Associates VC Fund · Menlo Park, California, United States · 39 investments in the past 12 months
Foundational partners to ambitious founders at every stage of company-building.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series B, Series A, Series C
  • United States, India, China
Portfolio highlights
  • beehiiv — Access the best tools available in email, helping your newsletter scale and monetize like never before.
  • SafeBase — Share your security posture with customers. Automate access to sensitive security and compliance documents with SafeBase.
  • ARRIS — ARRIS is an industrial engineering company that specializes in the fields of machinery manufacturing, automotive, and aerospace. It provides next-gen composites for mass-market applications including aerospace, automotive, sports, and consumer products. The company was founded in 2017 and headquartered in Berkeley, California.
F-Prime Capital VC Fund · Cambridge, Massachusetts, United States · 33 investments in the past 12 months
F-Prime Capital is a global venture capital firm investing in healthcare and technology, with a heritage that spans four decades.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series A, Series B, Series C
  • United States, United Kingdom, China
Portfolio highlights
  • Ashby — Ashby is a developer of recruitment software used for high-growth companies. It develops usable, enterprise-grade employment software that enables company leaders, recruiters, and hiring managers to run their hiring process significantly better. It was founded in 2018 and is based in San Francisco, California.
  • Expressable — Expressable is an online speech therapy practice for everyone with a communication disorder. It has pioneered a parent-focused care model that uses technology and education to integrate speech therapy techniques into children's daily lives, improving outcomes and experiences.The company was founded in 2019 and is headquartered in Austin,Texas.
  • Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
Atlas Venture VC Fund · Cambridge, Massachusetts, United States · 11 investments in the past 12 months
Atlas Venture is an early-stage venture capital firm that creates and invests in biotech startup companies led by promising entrepreneurs focusing on life sciences innovation. Its seed-led venture creation strategy rigorously selects and focuses investment on compelling opportunities to build scalable businesses and realize value.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Korro Bio — Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in proteinstructure and function across multiple tissues.In 2018,
  • Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
  • Diagonal Therapeutics — Diagonal Therapeutics pioneers a new era in medicine by advancing agonist antibody therapeutics targeting the root causes of devastating diseases. Discover our ground-breaking approach to reactivate critical biological pathways for transformative patient outcomes.
Khosla Ventures VC Fund · Menlo Park, California, United States · 75 investments in the past 12 months
Khosla Ventures invests in companies that are bold, early and impactful. The firm was started in 2004 by Vinod Khosla, co-founder of Sun Microsystems, to provide venture assistance to entrepreneurs. Headquartered in Menlo Park, Calif., Khosla Ventures invests in a range of areas including AI, climate, sustainability, enterprise, consumer, fintech,digital health, medtech and diagnostics, therapeutics and frontier technology.
Show more
Investment focus
  • Software, Health Care, Artificial Intelligence
  • Series A, Series B, Seed
  • United States, India, United Kingdom
Portfolio highlights
  • Karius — Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a majorthreat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.
  • Zeck — Create smarter, modern board updates optimized for superior readability to better engage and inform your board and investors. Run perfect board meetings.
  • YonedaLabs — Yoneda Labs suggests Reaction Conditions that work with no wet lab experimentation, and then we can help you optimise too, if necessary.
5AM Ventures VC Fund · Menlo Park, California, United States · 7 investments in the past 12 months
5AM Ventures is a venture capital firm that offers seed- and early-stage investments to its clients. The company’s client portfolio consists of firms in the biopharmaceutical, life sciences, medical technology, and research instrument industries. 5AM Ventures was founded in 2002 by John Diekman and Andrew Schwab and is based in California.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Silence Therapeutics — Silence Therapeutics plc is a United Kingdom-based ribonucleic acid (RNA) technology company. The Company is primarily involved in the research and development of pharmaceutical products. The Company's technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company has a has a genetictoolkit with its own therapeutic payloads to modulate gene expression up as well as down in preclinical in vivo models, and delivery systems for various organs and cell types.
  • Latigo Biotherapeutics — Operator of a drug discovery company intended to develop novel, non-opioid therapies for chronic pain. The company utilizes unique, translated insights to provide a differentiated approach to targeting therapeutics across the blood-nerve barrier, enabling patients to get access to a pain management therapy that does not create addiction, dependenceor tolerability.
  • Adverum Biotechnologies — At Adverum, we are driven to establish ocular gene therapy as a new standard of care for debilitating retinal diseases.
Polaris Partners VC Fund · Boston, Massachusetts, United States · 20 investments in the past 12 months
Polaris Partners invests in healthcare and biotechnology companies. Their healthcare portfolio companies' care delivery models include digital health, consumer-centric businesses, patient-provider solutions, data science, and analytics. Their life sciences and biotechnology portfolio companies focus on molecules and platforms, therapeutics,and genomics.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series B, Series A, Series C
  • United States, Ireland, Singapore
Portfolio highlights
  • Lore — Lore Health is a startup that combines artificial intelligence (AI) technology with social media to build a welcoming, encouraging, and judgment-free community where individuals may meet others who share their interests.
  • ByHeart — ByHeart operates as a fully integrated infant nutrition company. It is dedicated to translating leading nutrition science and breastmilk research into evolved foods and formulas to support babies’ health and parents’ peace of mind. Its products strive to be next to nature made from hand-picked ingredients using small-batch blending and sit at theforefront of immune, microbiome, cognitive, and digestive health.The company was founded in 2016 and is headquartered in New York.
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
RA Capital Management VC Fund · Boston, Massachusetts, United States · 68 investments in the past 12 months
RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series C, Series A
  • United States, United Kingdom, China
Portfolio highlights
  • Gameto — Gameto is a new breed of biotechnology company in female reproductive longevity
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Bicycle Therapeutics — Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
MPM Capital VC Fund · Cambridge, Massachusetts, United States · 7 investments in the past 12 months
Powering Breakthroughs in Life Sciences
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
  • Firefly Bio — Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders.
  • Frontier Medicines — Frontier Medicines is boldly advancing science to defeat disease by pioneering innovations in precision-based medicines to target undruggable therapies
Innova Memphis VC Fund · Memphis, Tennessee, United States · 2 investments in the past 12 months
Founded in 2007 by the Memphis Bioworks Foundation, Innova is a pre-seed, seed and early-stage investor focused on starting and funding high-growth companies in the Biosciences, Technology and AgBio fields across the state of Tennessee. Innova links capital with great ideas to create groundbreaking products and services.At Innova we invest instart-up companies, help them grow, and then assist them in linking with established corporations for licensing, buy-outs or further investments. We provide the synergy of experienced management, market expertise and venture capital to accelerate the development of new products and services into viable business units that can stand on their own and then take their place with a mature market leader, if desired.Whether an innovation is still on the drawing board or stalled in the market place the Innova staff has the expertise, skills, and experience to envision and create a functioning business unit that is prepared to thrive in the market place. Technical know-how, market-proven staffing, and "just-right" funding assure the greatest chance possible for success.
Show more
Investment focus
  • Health Care, Medical, Medical Device
  • Seed, Pre-Seed, Convertible Note
  • United States, Argentina, United Kingdom
Portfolio highlights
  • Rantizo — Fly more acres, deliver better service. The equipment, tools, and expertise you need to be the grower's first call for drone spray services.
  • iYOTAH Solutions — iYOTAH Solutions is a transformational SaaS technology company that connects data to help the animal protein industry thrive.
  • Glanris — Glanris developed a completely green, non-toxic, filtration media for water purification from an agriculture by-product. This agricultural product is grown around the world, is plentiful, and can be used locally to ensure clean drinking water in developing countries. It also gives local farmers a significant additional income source for a productthat today they are throwing away.This media has been independently tested over the last two years of development and is ready for production.
Qiming Venture Partners VC Fund · Shanghai, Shanghai, China · 49 investments in the past 12 months
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more
Investment focus
  • Health Care, Biotechnology, Medical
  • Series B, Series A, Series C
  • China, United States, Hong Kong
Portfolio highlights
  • GenEditBio — GenEditBio is a biotech company that specializes in providing curative gene editing based solutions for genetic diseases.
  • Brise Pharma — Brise Pharma operates in the scientific research and technical service industry.
  • Shengshu Technology — Shengshu Technology is an artificial intelligence solution provider that focuses on the creation of multi-modal generative big models and application products. It offers broad services to institutional businesses and technical service providers in specific industries.
Novartis Venture Fund VC Fund · Basel, Basel-Stadt, Switzerland · 4 investments in the past 12 months
Learn about the approach the Novartis Venture Fund takes to investing in innovative life science companies developing biotechnology and biopharmaceutical therapeutics that address unmet patient needs.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • Hyku — Hyku Biosciences is developing the next generation of covalent medicines by targeting histidine, tyrosine and lysine binding pockets in disease-causing proteins.
  • Hepalink — Hepalink is a manufactures ultra-pure pipeline control systems based on semiconductors and pan-semiconductor liquid circuits.
  • Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.
Third Rock Ventures VC Fund · Boston, Massachusetts, United States · 3 investments in the past 12 months
Third Rock Ventures is a leading healthcare venture firm focused on advancing disruptive areas of science and medicine to deliver breakthroughs to patients.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • Rapport Therapeutics — Precision medicines to match the complexity of the human brain.
  • Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
  • Synnovation Therapeutics — Synnovation Therapeutics is a precision oncology company focused on small molecule therapies optimized to target key driver mechanisms in cancers. It is dedicated to the discovery and development of therapeutics that can improve the lives of people with cancer. Leveraging its deep expertise in medicinal chemistry, cancer biology, andpatient-focused precision medicine, it builds a diverse pipeline of novel small-molecule targeted therapies. It aims to efficiently advance these agents into clinical trials with the goal of transforming cancer patient care.
M Ventures VC Fund · Amsterdam, Noord-Holland, The Netherlands · 16 investments in the past 12 months
Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Switzerland, United Kingdom
Portfolio highlights
  • LabGenius — Finding the next generation of drugs with machine learning, synthetic biology and laboratory automation
  • Outrun TX — Outrun TX develops a platform for the identification of therapeutics that selectively target the protein degradation pathway.
  • Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
UK Innovation & Science Seed Fund VC Fund · Harwell, Oxfordshire, United Kingdom · 12 investments in the past 12 months
UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Funding Round, Series A
  • United Kingdom, United States
Portfolio highlights
  • ExactTrak — ExactTrak Embedded command and control of mobile devices, even when they are turned off.
  • Presymptom Health — Presymptom Health is a pioneering medtech company that creates diagnostic tests to detect illnesses earlier to help save lives.
  • Oxford Space Systems — Oxford Space Systems is a multi-award-winning, record-breaking venture capital backed, space tech business that's developing a new generation of deployable antennas and space structures for the global satellite industry. Using both innovative design techniques such as origami and novel proprietary materials developed by the company, OSS'structures are lighter, less complex and lower cost than alternatives in commercial demand. Founded in late 2013, OSS set a record for the space sector with it's AstroTube Boom: the fastest development of a new product from concept to successful deployment on orbit in under 30 months. Today, the 18 strong and growing OSS team is a diverse mix of international graduates and experienced space industry professionals, with over 100 years of combined space sector experience. OSS investors include a small syndicate of UK venture capital funds together US based investors, Space Angels. Oxford Space Systems has successfully completed a number of UK government supported co-developments with leading European satellite builders as well straight commercial contracts in both Asia and the US. As part of its planned expansion, OSS move into its own custom facility at the Harwell Space Cluster in August 2018, giving it the largest clean room at the cluster. The facility will meet required security standards to undertake UK government defense & security contracts. .
Bpifrance VC Fund · Maisons-alfort, Ile-de-France, France · 71 investments in the past 12 months
Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.
Show more
Investment focus
  • Software, Information Technology, Health Care
  • Funding Round, Seed, Series A
  • France, United States, Switzerland
Portfolio highlights
  • FlexAI — We are unlocking the future of Machine Intelligence by rearchitecting the compute infrastructure
  • 52 Hertz — 52 Hertz has developed the Talkie-Divy, an underwater communications device that enhances safety, fun, and enjoyment in scuba diving, incorporating technologies directly adaptable to scuba diving regulators, while also considering environmental issues.
  • Docent — Docent is the first AI-powered mobile application to offer a fully-personalized experience for discovering, accessing and collecting contemporary masterpieces.
Canaan Partners VC Fund · Menlo Park, California, United States · 19 investments in the past 12 months
Canaan is an early stage venture capital firm that invests in entrepreneurs with visionary ideas. With $5B under management, a diversified fund and over 190 exits to date, Canaan has invested in some of the world's leading technology and healthcare companies over the past 30 years. Canaan’s focus areas include fintech, enterprise/cloud,marketplaces, frontier tech, biopharma, digital health, and medtech.
Show more
Investment focus
  • Software, Biotechnology, Health Care
  • Series A, Series B, Series C
  • United States, Israel, United Kingdom
Portfolio highlights
  • Truveris — Truveris is a leading digital health company focused on delivering truth and clarity in pharmacy.
  • Reibus — Reibus is the leading platform for buying and selling steel and other metals, with end-to-end services including logistics and financing.
  • Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.
Sequoia Capital China VC Fund · Beijing, Beijing, China · 37 investments in the past 12 months
We help founders build enduring companies.
Show more
Investment focus
  • Biotechnology, Health Care, Artificial Intelligence
  • Series A, Series B, Series C
  • China, United States, Australia
Portfolio highlights
  • Wuxi Gongwang — Wuxi Gongwang inductive sensor developer offering high-precision, oil and dust-resistant products for various industries, including aerospace, automotive, medical care, and more.
  • Huaxuan Sensing — Huaxuan Sensing is a sensor technology company that focuses on the development of resolver sensors for the new energy automobile industry.
  • Martial Arts Awakening — Martial Arts Awakening is a blockchain game developer focused on the long-term development of blockchain, Web3.0, Metaverse, and NFT ecosystems.
HTGF | High-Tech Gruenderfonds VC Fund · Bonn, Nordrhein-Westfalen, Germany · 55 investments in the past 12 months
The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise,entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Show more
Investment focus
  • Software, Information Technology, Biotechnology
  • Seed, Series A, Funding Round
  • Germany, Switzerland, United States
Portfolio highlights
  • Seqana — X-Ray-Vision” Monitoring SaaS, for Soil Organic Carbon. To fight climate change, we enable Project Developers and Agri-Food Corporates to measure and understand soil carbon sequestration in an ultra low cost, fast, precise, and affordable way. At planetary scale!
  • JUPUS — As the first legal AI secretary in Europe, JUPUS automates the entire process from initial client contact to the complete file. Lawyers are supported by an AI chatbot, an online appointment booking tool, and an AI platform that automatically collects and processes inquiries, information, and documents, facilitating automated communication withclients.
  • Synthara Technologies — Synthara is a Zurich-based artificial intelligence (AI) company that provides system-level solutions for businesses to enhance their products or services with smart features. The company portable and wearable gadgets such as virtual reality headsets, small wireless monitoring cameras, sensor networks, have limited smart features because computingpowerful algorithms cannot be run on them. Synthara IPs provide server-class performance with an extremely low energy requirement for neural networks (10 TOPs/Watt).
BioAdvance VC Fund · Philadelphia, Pennsylvania, United States
BioAdvance actively invests venture capital in therapies, medical devices, research tools, diagnostics and health IT in the Mid-Atlantic region.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Funding Round, Series A
  • United States, Canada
Portfolio highlights
  • Senzo — SENZO HEALTH HAS DEVELOPED A REVOLUTIONARY LATERAL FLOW TEST WHICH DELIVERS THE SAME ACCURACY AS LABORATORY-BASED PCR, WITH RESULTS AVAILABLE WITHIN 10 MINUTES, AT A FRACTION OF THE COST.
  • KayoThera — KayoThera is a biotechnology company developing therapeutics used to cure late-stage and metastatic cancers. Its programs work on inhibiting a key enzyme that is responsible for protecting the cancer cells and depleting regulatory T-cells that intends to cure hitherto incurable cancers and give hope to patients. The company's mission is todevelop the first-in-class immuno- and targeted therapies to drive cures in advanced cancersKayoThera was founded in 2019 and is headquartered in Princeton, New Jersey.
  • Palvella Therapeutics — Palvella Therapeutics is committed to developing safe and effective therapies that specifically target the root cause of genetic skin diseases.
Takeda Ventures VC Fund · San Diego, California, United States
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Funding Round
  • United States, United Kingdom, Israel
Portfolio highlights
  • Cerevance — Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.The company's therapeutics applies it's technology called NETSseq to reveal transcriptional and epigenetic differences between specific cell types in mature human brains, enabling healthcare providers to detect and tackle theearly onset of various neurological diseases.
  • OncoResponse — OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer.
  • Larkspur Biosciences — Larkspur's strategy focuses on the particular ways in which tumours hijack the immune system by developing precision immunotherapies for molecularly defined patient groups to overcome the bottlenecks that allow the tumour to subvert the immune system.
Lux Capital VC Fund · New York, New York, United States · 37 investments in the past 12 months
Lux Capital manages over $5 billion in assets focused on founding, seed, early-stage, and growth investments at the intersection of technology and the sciences. Lux takes an active role in helping entrepreneurs build successful businesses in high-growth sectors. Its investment team has built over 20 companies from scratch. Lux's investmentstrategy ensures portfolio companies are better connected, have a deeper insight, and command industry leadership faster than their competitors.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Seed, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Nominal — A faster, more reliable way to review test data for mission-critical systems.
  • Summer Health — Get answers from an expert, board-certified pediatricians in 15 minutes. From child health to development, Summer Health gets you answers any time, day or night.
  • Xaira Therapeutics — Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence to learn the language of life and transform how we treat disease. The company seeks to rethink the drug discovery and development process from end-to-end by bringing together leading talent across three core areas: machine learning research tobetter understand biology, expansive data generation to power new models, and robust therapeutic product development to treat disease. Xaira is headquartered in the San Francisco Bay Area.
Pfizer Venture Investments VC Fund · New York, New York, United States · 8 investments in the past 12 months
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, United Kingdom, Switzerland
Portfolio highlights
  • Capstan Therapeutics — Capstan Therapeutics is advancing precision in vivo cell engineering to develop therapeutics for a broad range of disease categories with unmet or underserved clinical need.
  • MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
  • Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.
Boehringer Ingelheim Venture Fund VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 2 investments in the past 12 months
The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Seed
  • United States, Germany, Belgium
Portfolio highlights
  • Actym Therapeutics, Inc. — Actym Therapeutics is developing key biotech to help target intractable immune pathways in the tumor microenvironment.
  • smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
  • Glox Therapeutics — Developing novel precision antibiotics based on protein bacteriocins, to target Gram-negative Antimicrobial Resistant (AMR) pathogens.
Google Ventures VC Fund · Mountain View, California, United States · 53 investments in the past 12 months
GV supports innovative founders moving the world forward.
Show more
Investment focus
  • Software, Health Care, Biotechnology
  • Series A, Series B, Seed
  • United States, United Kingdom, Canada
Portfolio highlights
  • StrongDM — Manage access to any server, database, or Kubernetes instance in minutes. Fully auditable, replayable, secure, and drag-and-drop easy.
  • Delphia Therapeutics — Delphia is pioneering activation lethality - a next-generation precision medicine approach that targets cancer's surprising vulnerability to oncogene overactivation.
  • BridgeBio Oncology Therapeutics — BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.
Fifty Years VC Fund · San Francisco, California, United States · 8 investments in the past 12 months
WE BACK HEROES using technology to solve the world's biggest problems
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Germany, Canada
Portfolio highlights
  • Nabla Bio — Nabla is an autoreverse platform that enables the rapid discovery of previously unattainable protein variants with supernatural qualities. Nabla Bio makes new medicines and improve nutrition by engineering novel proteins.
  • The Bot Company — The Bot Company a household robot startup.
  • Cosmic Aerospace — Cosmic Aerospace is a pioneering aerospace technology company dedicated to advancing the boundaries of propulsion systems and enabling innovative solutions for space exploration. The company collaborates with leading space agencies, research institutions, and commercial partners to design, test, and implement these groundbreaking technologies.
Lilly Asia Ventures VC Fund · Shanghai, Shanghai, China · 18 investments in the past 12 months
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Series C
  • China, United States, Hong Kong
Portfolio highlights
  • ProfoundBio — ProfoundBio is an oncology biotherapeutics company focused on the development of novel antibody-based therapeutics with curative potential for patients with cancer.
  • Targeting One — Targeting One is an in-vitro diagnostic product developer.
  • Healingovation — Healingovation is a med-tech company that specializes in the development and manufacturing of surgical robots, intelligent diagnosis and treatment equipment.
Andreessen Horowitz VC Fund · Menlo Park, California, United States · 99 investments in the past 12 months
Andreessen Horowitz (a16z) is a venture capital firm in Silicon Valley, California, investing in bold founders, innovators, and entrepreneurs building the future through technology.
Show more
Investment focus
  • Software, Information Technology, Internet
  • Series A, Seed, Series B
  • United States, United Kingdom, Canada
Portfolio highlights
  • Exowatt — Modular Full-Stack Renewable Energy Solutions for Commercial and Industrial Applications
  • SPF META — SPF META develops blockchain games using blockchain technologies.
  • Cape — Cape develops privacy-enabling technology that allows users to reclaim their privacy and security on electronic devices. The company's technology communicates with electronic devices while maintaining anonymity and privacy without compromising user experience.
Sofinnova Investments VC Fund · Menlo Park, California, United States · 6 investments in the past 12 months
Sofinnova deploys human and financial capital to turn dreams into drugs. We are a clinical-stage biopharmaceutical venture capital firm with approximately $2B in assets under management and committed capital.
Show more
Investment focus
  • Biotechnology, Health Care, Pharmaceutical
  • Series B, Series A, Series C
  • United States, France, Switzerland
Portfolio highlights
  • Avenzo Therapeutics — Developing the next generation of oncology therapies for patients.
  • Seaport Therapeutics — Seaport Therapeutics operates as a clinical stage biopharmaceutical company.
  • Aeovian Pharmaceuticals — Aeovian is a San Francisco based biopharmaceutical company developing novel and highly selective therapeutics modulating mTORC1 pathway.
EQT Life Sciences VC Fund · Amsterdam, Noord-Holland, The Netherlands · 12 investments in the past 12 months
EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, The Netherlands, Switzerland
Portfolio highlights
  • Phagenesis — Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.
  • Onera Health — Introduction to Onera sleep diagnostics and monitoring solutions
  • Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
SR One VC Fund · Cambridge, Massachusetts, United States · 5 investments in the past 12 months
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Avalyn Pharma — This does NOT display on the home page
  • Nimbus Therapeutics — Nimbus Discovery is now Nimbus Therapeutics to reflect our transition into a clinical stage company. Nimbus Therapeutics is a biotechnology company headquartered in Cambridge, Mass., that is pioneering a new computational technology-driven paradigm to rapidly advance a diverse pipeline of novel small molecule product candidates into clinicaldevelopment. We are designing highly selective and potent medicines to disrupt known drivers of serious diseases, including metabolic disease, cancer and immune-inflammatory disorders.
  • Odyssey Therapeutics — Odyssey Therapeutics is developing innovative medicines to make extraordinary leaps in outcomes for patients with cancer inflammatory diseases
DCVC VC Fund · San Francisco, California, United States · 13 investments in the past 12 months
We are deep tech venture capital.
Show more
Investment focus
  • Software, Artificial Intelligence, Health Care
  • Seed, Series A, Series B
  • United States, Canada, United Kingdom
Portfolio highlights
  • Fervo Energy — Fervo Energy delivers 24/7 carbon-free energy through development of next-generation geothermal projects.
  • Kairos Aerospace — Kairos Aerospace provides large-scale, aerial monitoring of methane emissions. The company completed the first-ever basin-wide aerial survey for methane detection in its 2019 survey of the Permian Basin. Kairos Aerospace’s mission is to improve operational excellence for the oil and gas industry with cost-effective, efficient methane reductions atscale.
  • Relation Therapeutics — Relation uses machine learning to develop drugs for pressing unmet need.
Parkwalk Advisors VC Fund · London, England, United Kingdom · 7 investments in the past 12 months
Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.
Show more
Investment focus
  • Biotechnology, Health Care, Software
  • Seed, Series A, Series B
  • United Kingdom, United States, Philippines
Portfolio highlights
  • Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
  • Adsilico — Adsilico redefines medical device innovation.
  • Wayland Additive — Wayland Additive Limited is a West-Yorkshire based company pushing the boundaries of electron beam 3D printing. Wayland’s goal is to develop, manufacture and sell metal Additive Manufacturing (“AM” – 3D printing) machines to industrial end-users such as major players in the aerospace and medical industries.
Seventure Partners VC Fund · Paris, Ile-de-France, France · 4 investments in the past 12 months
Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.
Show more
Investment focus
  • Biotechnology, Health Care, Software
  • Series A, Series B, Funding Round
  • France, United States, Germany
Portfolio highlights
  • ID5 — ID5 provides a comprehensive suite of identification services designed to improve to improve addressability and measurement across all environments
  • Peptobiotics — We make agriculture more productive, humane and sustainable by promoting growth and protecting against pathogens using a new new type of antibiotic alternative that does not cause resistance. Our recombinant peptides are synthetic biology products manufactured in a patent pending precision fermentation process. We are launching a range of products across livestock and aquaculture in Asia.
  • Tubulis — Reimagining Antibody Drug Conjugates Tubulis generates uniquely matched protein-drug conjugates through the combination of novel proprietary technologies and disease-specific biologic insight. Our goal is to expand the therapeutic potential of antibody-drug conjugates (ADCs) by increasing design flexibility while overcoming constraints of toxicity, efficacy and indication. Tubulis will build new conjugates to fill its pipeline and
KdT Ventures VC Fund · Austin, Texas, United States · 6 investments in the past 12 months
KdT Ventures is the standard for early-stage frontier science investing.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Seed, Series A, Series B
  • United States, Israel, Germany
Portfolio highlights
  • Elegen — Elegen is powering the bioeconomy with high-accuracy DNA synthesis that delivers industry-leading speed, length, and quality.
  • Motif Neurotech — Motif Neurotech is a company that develops minimally invasive bioelectronic implants for monitoring and treating severe mental illnesses.
  • Radar Therapeutics — Precision-targeted, smart therapies to conquer the world's most intractable diseases.
Hatteras Venture Partners VC Fund · Durham, North Carolina, United States
Hatteras Venture Partners is a venture capital firm based in Research Triangle Park, NC, with a focus on biopharmaceuticals, medical devices, diagnostics, and related opportunities in human medicine. Founded in 2000, the firm consists of an experienced team with a broad and complementary skill set that is particularly relevant to buildingsuccessful new biomedical companies. The Hatteras Venture Partners team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With three funds, the firm has more than $120 million under management.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series A, Series B, Funding Round
  • United States, Canada
Portfolio highlights
  • 410 Medical — 410 Medical has developed a simple, intuitive solution that allows a single healthcare provider to rapidly deliver fluid to critically ill patients, improving care, and saving lives. Their device allows fast set-up, improves resuscitation speed, minimizes provider fatigue, and frees providers to address other patient care issues simultaneously.This solution is particularly useful in pre-hospital settings and the emergency department and where speed is critical and resources may be limited.It was founded in 2013 and headquartered in Durham, North Carolina.
  • Myeloid Therapeutics — Myeloid Therapeutics is an immunology company focused on combining immunologic insights with cutting-edge technologies to harness myeloid cells to eradicate cancer and other diseases. The Company's ATAKTM platform technology can be broadly applied, and it is initially advancing a cell therapy program for T cell lymphoma and a primed monocyteapproach to treat glioblastoma. The ATAK platform is scalable to multiple treatment modalities and other disease areas in collaboration with partners.
  • Veralox Therapeutics — Veralox Therapeutics develops small molecule therapeutics that treat the underlying pathologies of thrombosis and type one diabetes. Based on an understanding of the molecular mechanisms of these diseases, these efforts will lead to new treatment paradigms and better outcomes for patients.
Casdin Capital VC Fund · New York, New York, United States · 4 investments in the past 12 months
Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments. Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets undermanagement.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, France, China
Portfolio highlights
  • ROME Therapeutics — ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier inbiology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning.
  • Remix Therapeutics — Remix Therapeutics is a biotechnology company that develops novel small molecule therapies designed to reprogram RNA processing and treat disease in entirely new ways.
  • BridgeBio Oncology Therapeutics — BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.
The Column Group VC Fund · San Francisco, California, United States · 7 investments in the past 12 months
The Column Group is a leading venture capital firm dedicated to creating the next generation of biotechnology companies
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series A, Series B, Series C
  • United States
Portfolio highlights
  • Kenai Therapeutics — Kenai Therapeutics focuses on developing therapies for neurodegenerative movement disorders. The company provides off-the-shelf neuron replacement medicines as effective disease-modifying treatments for neurological disorders, providing doctors with techniques to treat diseases like Parkinson's.
  • Accent Therapeutics — Accent Therapeutics is a biopharmaceutical company developing oncology-focused, small molecule therapies in the emerging field of epitranscriptomics. This field of biology encompasses post-transcriptional chemical modifications of RNA that provide cells with a unique mechanism for regulating proteins critical for cellular growth anddifferentiation. By targeting cancer-linked RNA-modifying proteins (RMPs) with precision therapies, they aim to translate extraordinary science into life-changing therapies for patients.
  • Neurona Therapeutics — Neurona Therapeutics is a pre-clinical stage biotechnology company that was founded by four neuroscientists and stem cell pioneers at The University of California, San Francisco. They are focused on the discovery and development of cell-based therapies to treat intractable neurological disease. Its initial aim is to generate therapeuticcompositions of a specific type of nerve cell (or neuron) for targeted delivery into the injured nervous system. Based on nearly two decades of research, they believe that particular subpopulations of neurons have the unique ability to integrate and repair dysregulated neural circuits. Its talented team of scientists, scientific advisors, and board directors is working to accelerate breakthrough treatments for patients with significant unmet medical needs.
Connecticut Innovations VC Fund · Rocky Hill, Connecticut, United States · 13 investments in the past 12 months
At Connecticut Innovations, we see venture capital the way you see your business. Like no one else. We invest in innovative biotech, IT, and other industries.
Show more
Investment focus
  • Health Care, Biotechnology, Software
  • Series A, Seed, Funding Round
  • United States, Israel, Canada
Portfolio highlights
  • Conduce Health — Conduce Health is a multi-specialty value-based care marketplace providing turnkey solutions for primary care organizations.
  • DeepLook Medical — Enhancing Medical Imaging with Revolutionary Software: DeepLook Medical envisions a future where data-driven imaging enables accurate, efficient, and personalized care across the entire treatment pathway.
  • Manifest Technologies — Manifest Technologies advances AI-powered computational neuroimaging system that quantifies neural and symptom data.
Frazier Healthcare Partners VC Fund · Seattle, Washington, United States
With its purpose-driven culture and deep industry expertise, Frazier Healthcare is the preferred partner to profitable healthcare companies.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Post-IPO Equity
  • United States, Canada, Ireland
Portfolio highlights
  • Metagenomi — Metagenomi is using the power of metagenomics and machine learning to discover novel genome editing systems.
  • Pardes Biosciences — Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines.The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
  • New Amsterdam Pharma — NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
Forbion Capital Partners VC Fund · Naarden, Noord-Holland, The Netherlands · 12 investments in the past 12 months
Impacting the future of medicine.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Series C
  • United States, United Kingdom, The Netherlands
Portfolio highlights
  • Pheon Therapeutics — Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers. Its lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types.The company was founded in 2022 and is based in London,England.
  • Bicycle Therapeutics — Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need.The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.
  • Progentos Therapeutics — Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
HealthCap VC Fund · Stockholm, Stockholms Lan, Sweden
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more
Investment focus
  • Biotechnology, Health Care, Medical
  • Series B, Series A, Funding Round
  • United States, Sweden, France
Portfolio highlights
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
  • Rampart Bioscience — Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases. It also offers proprietary development and delivery platforms, which together, create optimized therapeutics in a revocable, non-viral format. It also assists patients with genetically driven diseases by integrating capabilities from avariety of key scientific disciplines including gene delivery, protein sciences, and clinical translation.
Amgen Ventures VC Fund · San Francisco, California, United States
Amgen Ventures is a venture capital investment arm of Amgen Inc. specializing in investments in early and later stage companies. The firm primarily invests in the biotechnology sector with a focus on discovering and developing human therapeutics with a focus on oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, andcardiovascular therapeutics. In oncology and hematology it focuses on novel therapeutics including signal transduction, cell cycle, and apoptosis; hematopoiesis including anemia, neutropenia, and stem cell mobilization; and supportive care including mucositis and cachexia. In nephrology the firm focuses on renal failure and hyperparathyroidism. For inflammation the firm focuses on rheumatoid arthritis, psoriasis, systemic lupus erythematosus, inflammatory bowel disease, multiple sclerosis, asthma and COPD, and osteoarthritis. Under cardiovascular, it focuses on acute coronary syndromes, dyslipidemia, and heart failure and under metabolic disorders it focuses on diabetes, metabolic syndrome, and osteoporosis. The focus on neuroscience included pain including neuropathic and inflammatory, alzheimer's disease, parkinson's disease, sleep disorder, cognition, and schizophrenia. In discovery research and technology the firm focuses on early-stage drug discovery collaborations, innovative chemical entity collections, diagnostics and biomarkers, novel antibody platforms, assay biologicals and devices, and target-focused structural biology and computational tools. It primarily invests in the North America, Europe, and the United Kingdom. The firm typically invests between $2 million and $3 million per transaction and may invest up to $10 million per company. It prefers to have an ownership stake of less than 15 % in its portfolio companies. Amgen Ventures was founded in 2004 and is based in San Francisco, California with additional offices in Seattle, Washington; Thousand Oaks, California; and Cambridge, Massachusetts.
Show more
Investment focus
  • Biotechnology, Health Care, Therapeutics
  • Series B, Series A, Series C
  • United States, Canada, United Kingdom
Portfolio highlights
  • Inversago Pharma — Inversago Pharma is a preclinical-stage, biotech company specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists.
  • Casma Therapeutics — Casma Therapeutics is a developer of a natural cellular process of autophagy to open new target areas for drug discovery and development. The company focuses on autophagy system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens as well as tries to arrest or reverse the progression of lysosomalstorage disorders, muscle disorders, inflammatory disorders and neurodegeneration, enabling physicians to address unmet medical needs.
  • Feldan Therapeutics — Feldan Therapeutics has developed a patented peptide-based technology platform, the Feldan Shuttle, which enables fast and safe intracellular delivery. The company's mission is to develop leading-edge therapeutic applications based on its proprietary platform, as demonstrated by its current pipeline of clinical programs taking advantage of theunique characteristics of the Shuttle.
Northpond Ventures VC Fund · Bethesda, Maryland, United States · 8 investments in the past 12 months
Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more
Investment focus
  • Biotechnology, Health Care, Life Science
  • Series A, Series B, Series C
  • United States, United Kingdom, Canada
Portfolio highlights
  • Totus Medicines — Applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.
  • SeLux Diagnostics — SeLux Diagnostics is a developer of the Next-Generation Phenotyping (NGP) platform that enables personalized antibiotic therapies for patients. The company was founded in 2014 and is based in Charlestown, MA.
  • Elephas — Elephas is a live tumor imaging company developing novel cancer diagnostic solutions to predict treatment outcomes and accelerate drug development.
Oxford Science Enterprises VC Fund · Oxford, Oxfordshire, United Kingdom · 11 investments in the past 12 months
Oxford Sciences Innovation is the world’s largest university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companiestaking on challenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Show more
Investment focus
  • Health Care, Biotechnology, Software
  • Seed, Series A, Funding Round
  • United Kingdom, United States, Finland
Portfolio highlights
  • Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology
  • Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
  • Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.
Investors by industry
Investors by country
Investors in Biotechnology by country
Angel investors in Biotechnology by country
VC Funds in Biotechnology by country